TOPICAL USE OF CHLORQUINALDOL* HARRY M. ROBINSON, JR., M.D. AND MARK B. HOLLANDER, M.D. PROCEDURE

Similar documents
EVALUATION OF TOPICAL DICHLOROXYQUINALDINE (STEROSAN) AS A THERAPEUTIC AGENT IN DERMATOLOGY* ARTHUR J. TRONSTEIN M.D.**

Contents. QAaptm-2. CAaptei-3. CAaptm-4. Cftapte%-5. Qfiaptvt-6. QhapteK-7. Qkaptefc-8 Clinical Immunology and Allergy 71

Alcortin A (iodoquinol and hydrocortisone), Novacort (hydrocortisone and pramoxine)

Table of Contents: Part 1 Medical Dermatology. Chapter 1 Acneiform Disorders. Acne. Acne Vulgaris. Pomade Acne. Steroid Acne

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate

CONDITIONS OF THE SKIN

and virus infections notable improvements, too, have been attained in our capacity and ability to suppress inflammation, dampen the effects of allergy

Rash Decisions Approach to the patient with a skin condition

My Algorithm. Questions to ask. Do you or your family have a history of?... Allergic rhinitis, Sensitive skin, Asthma Skin Cancer

Site and distribution: symmetrical, asymmetrical. Surface characteristics: smooth, scaly, warty

PRODUCT MONOGRAPH INCLUDING THE PATIENT MEDICATION INFORMATION VALISONE-G* CREAM

DATA SHEET. Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).

DIPROSONE OV Cream and Ointment do not contain preservatives, parabens or lanolin.

Subspecialty Rotation: Dermatology

A CLINICAL EVALUATION OF THE EFFECTIVENESS OF HYDRYLLIN IN THE TREATMENT OF A VARIETY OF DERMATOSES*

Sandostene an(! Sandostene in Combination with Calcium: Clinical Effect in Various Dermatoses

The Role of Low-Potency Topical Steroids in Day-to-Day Practice

Prescribing Information

PRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION. Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol

Index. Angiosarcoma diagnosis, 47 lymphedema-related vs. non-lymphedemarelated, 48

PRODUCT MONOGRAPH. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid

Report of a Round Table Discussion

PRODUCT MONOGRAPH DIPROSONE. Betamethasone Dipropionate Cream, Merck Standard, 0.05% W/W betamethasone (as dipropionate)

The side effects of prolonged used of systemic Corticosteroids

OCCUPATIONAL DERMATOSES

WR SKIN. DERMATOLOGY

Dermatology Syllabus for 5th Year Med Students

OCCUPATIONAL DERMATOSES

COURSE DESCRIPTION AND STUDY REGULATIONS

The skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis

An Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.

Course Regime. Course: SKIN AND VENEREAL DISEASES. Study Programme: Medicine. Year of the Course: 4 th study year.

THE LATE THERAPEUTIC RESULTS PRODUCED BY LOW VOLTAGE ROENTGEN RAYS AND OTHER FORMS OF THERAPY IN CERTAIN BENIGN CHRONIC SKIN DISEASES*

Original Article. Abstract. Introduction

Clinical profile of skin diseases in accident and emergency department attenders

Diagnose dermatologic conditions based on physical examination (visual recognition). The majority of the items will come from Group 1.

Your health is our priority

Core Safety Profile. AT/H/PSUR/0013/002 Date of FAR:

Bacterial Infections in Pediatric Dermatology. Patrick McMahon, MD Children s Hospital of Philadelphia

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE C SKIN CREAM. Betamethasone and Clioquinol Cream BP

Prevalence of skin disorders among primary school children in Diyarbakir, Turkey

Clinic Clinic Information Suitable for Referral Not Suitable for Referral

Objectives. Terminology. Recognize common pediatric dermatologic conditions. Review treatment plans Identify skin manifestations of systemic disease

Prescribing Information

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

Skin diseases among children attending the out patient clinic of the University of Nigeria teaching hospital, Enug

Topical Doxepin Prior Authorization with Quantity Limit Program Summary

A community study of prevalence and use of medical care

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect Cetyl alcohol For the full list of excipients, see section 6.1.

GROUP 15 TOPICAL PREPARATIONS

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory FLUTIVATE SKIN CREAM. Fluticasone Cream IP

ZOFLUT Cream (Fluticasone propionate)

DERMATOLOGY FOR THE NON-DERMATOLOGIST. Mackinac Island, Michigan The Grand Hotel. July 16 18, Participating Faculty

Diagnosis and Management of Common and Infective Skin Diseases in Children at primary care level

Rashes Not To Be Missed In Children

SUMMARY OF PRODUCT CHARACTERISTICS

BETNOVATE SKIN CREAM. Betamethasone Valerate Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION

Commonly Coded Conditions in Dermatology

five series of cases were studied. Many of the patients treated by one

A Clinical Study of Paediatric Dermatoses

Issues in Dermatology. Rhonda Lesniak, PhD, ARNP, FNP-BC, NCSN

Pediatric Dermatoses: A Study of 313 Cases

SUMMARY OF PRODUCT CHARACTERISTICS

Core Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:

Learning Circle: Jan 26, 2011 Childhood Eczema

Pediatric Dermatology. Wingfield Rehmus, MD MPH BC Children s Hospital

DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY. Daniel A. West, MD I HAVE NO RELEVENT RELATIONSHIPS WITH ANY COMPANIES

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE - S

Family Medicine End of Rotation

Atopic Dermatitis and Topical Antipsoriatics

Phototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions

PRESCRIBING INFORMATION. Cream 0.025% Topical Corticosteroid

Atopic dermatitis Usually starts t in early infancy Xerosis (dry skin) Pruritus Eczematous lesions

ATTACHMENT 1 SUMMARY OF PRODUCT CHARACTERISTICS

Eczema & Dermatitis Clinical features: Histopathological features: Classification:

Eczema. By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough

ORIGINAL INVESTIGATION. Most Common Dermatologic Problems Identified by Internists,

PRODUCT MONOGRAPH. (Desonide Cream and Ointment) 0.05% (w/w) Glucocorticoid Royalmount Ave, Suite #100 July 29, 2014 Montreal, Quebec H4P 2T4

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

eczema the basics 2EE6E629CEA25112ABD0B8EB Eczema The Basics 1 / 6

Chapter 8 Skin Disorders and Diseases

BETNOVATE Betamethasone 17-valerate

50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).

Chapter 40. Alterations of the Integument in Children

No Disclosures. Objectives 12/13/2016. Pregnancy-Associated and Other Dermatoses of Young Women

Sick Call Screener Course. Integumentary System

SUMMARY OF PRODUCT CHARACTERISTICS. Each gram of ointment contains 1 mg of mometasone furoate and 50 mg of salicylic acid

PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: DERMATOLOGY/EMERGENCY MEDICINE/RHEUMATOLOGY

Dermatology Pearls. Leah Layman, ARNP Jefferson Healthcare Dermatology June 21, 2018

Dermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015

Eczema Itchin' For A Cure By Suzy Cohen

Phototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions

COMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio

PENICILLIN IN SKIN DISEASES By I. R. MARRE, M.R.C.S., L.R.C.P.

Workbook Answers Chapter 6. Diseases and Conditions of the Integumentary System

PRESCRIBING INFORMATION. ratio-topisone. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid

Transcription:

TOPICAL USE OF CHLORQUINALDOL* HARRY M. ROBINSON, JR., M.D. AND MARK B. HOLLANDER, M.D. In 9, Jadassohn and his co-workers () published a report relative to a new preparation which they found to be effective in the treatment of the pyodermas. This preparation was laboratory-tested at Basle and ZUrich and found to have both in vitro and in vivo bacteriostatic activity against staphylococci. Jadassohn and his co-workers did comparison studies with another oxyquinoline derivative, iodochlor-oxyquinoline, in the treatment of pyodermas and found 5, 7-dichioro- -hydroxyquinaldine (chlorquinaldol) to be superior. They stated that the ointment containing this material had anti-mycotic value, particularly in mixed infections produced by fungi and bacteria. Metaxas (), Felkel (), Sigg (), Schubert (5), and others (, 7, ) have confirmed these results. Less than three percent of the patients studied by Pierce (9) developed "sensitization or irritation reactions." Leifer and Steiner () reported their experiences with two patients who had become sensitized to other oxyquinoline derivatives and were subsequently proved to have positive reactions to another derivative, 5-chioro- -hydroxyquinaldine as well. This was considered indicative of group sensitivity to the halogenated oxyquinolines. This study was conducted to determine the value of chlorquinaldol in dermatologic therapy. PROCEDURE Patients studied Chlorquinaldol was supplied in two vehicles:. Petrolatum-beeswax ointment base containing % of the active ingredient; the finished product was light yellow in color.. A vanishing cream base containing % of the active ingredient; this preparation was white in color, but turned a pale yellow after application to the skin. Patients selected 75 white and Negro patients of all ages with various dermatoses were included in this study. The patients were obtained from the out-patient department of the University Hospital and from other affiliated hospitals. Members of the dermatology staff also used these preparations in the treatment of their private patients. Whenever possible, the diagnoses and treatment results were confirmed * From the Division of Dermatology, Department of Medicine, University of Maryland School of Medicine. This study was supported by a grant-in-aid from the Medical Research Department of Geigy Pharmaceuticals, Division of Geigy Chemical Corporation, New York, who supplied the chlorquinaldol as Sterosan Cream and Ointment. Received for publication August, 955.

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY by other members of the staff. This report represents a compilation of all of these results. Method of treatment Treatment was initiated in 9 patients with the oily base ointment and in 5 with the greaseless base cream. The oily base preparation of chlorquinaldol was used initially in all instances in which the dermatoses were dry, and the greaseless base preparation was used initially in cases in which the dermatoses were moist. In some instances, such as the treatment of the pyodermas or other dermatoses where the underlying condition was complicated by secondary pyogenic infection, it proved desirable to initiate therapy with the oily base ointment and, after the pyoderma cleared, to continue treatment with the greaseless base cream. In this latter group of patients, instructions were given to remove the surface detritus by compressing with warm water prior to the application of the ointment. In all other dermatoses, the preparation was applied two or three times daily. RESULTS Pyogenic disorders (Table I) Chlorquinaldol was effective in the treatment of impetigo contagiosa and other pyodermas, including infectious eczematoid dermatitis, dermatitis exfoliativa neonatorum and paronychia. Of a total of patients initiating therapy for pyogenic disorders, patients returned. From this latter group, improvement was noted in 9, partial improvement in, and showed no improvement. TABLE I Results of treatment with c.hlorquinaldol in pyogenic skin disorders Diagnosis Starting Treatment Impetigo contagiosa 9 5 9 Seborrheic dermititis 5 9 Pyodermas (extensive).... 7 5 9 Epidermophytosis, secondarily infected Otitis externa 5 7 5 Atopic dermititis, infected Infectious eczematoid dermatitis 9 7 5 Paronychia Dermatitis exfoliativa neonatorum Pustular bacterid s 9

TOPICAL USE OF CHLOHQUINALDOL 5 In atopic dermatitis, seborrheic dermatitis, epidermophytosis and otitis externa in which the underlying dermatosis was complicated by secondary pyogenic infection, the preparations were of value in eradicating the infection in from five to twelve days. Results obtained in the study of dermatitis exfoliativa neonatorum (Ritter's Disease) confirmed those reported by earlier investigators (). Prompt improvement was noted and all lesions underwent involution in two weeks. Two patients with pyogenic paronychia and with monilial paronychia were also treated. The patients with the pyogenic infection recovered completely, while those with monilial infection did not respond. Non-p yogenic disorders (Table II) One result observed with both the ointment and the cream was relief of pruritus. In individuals who had pruritus without any underlying dermatosis, there was little or no relief from itching. A topic dermatitis: 7 patients with atopic dermatitis began treatment in this series, and were lost from observation. Of the remaining 9, 5 were definitely improved, were partially improved and were not benefited. The most notable effect in this condition was relief from pruritus. Topical therapy with chlorquinaldol was used as an adjunct to afford the patient relief while a search was made for etiological factors. Contact dermatitis: patients with contact dermatitis began treatment with the ointment or cream, but were lost from observation. Of the 7 cases followed, were completely relieved of symptoms, were partially improved TABLE II Results of treatment with chtorquin.aldol in non-pyo genie skin disorders. Diagnosis Cases Starting Treatment Cases Lost I Cases Improved Partially Not Tmproved Improved Followed Local Irritation H - 'P I" ) Atopic dermatitis Contact dermatitis (all causes) Lichen simplex chronicus (neurodermatitis) Psoriasis Mummular eczema Stasis dermatitis Pityriasis aiha Erythrodermia desquamativa Pruritus ani Miliaria rubra 7 7 9 7 5 5 5 7 7 9 7 s i

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY and patients failed to improve. During the course of treatment, all other medication was withheld and, whenever possible, irritating factors such as soap, detergents and solvents were eliminated from contact with the patients. Lichen simplex chronicus: Of patients, were lost from observation. 5 of the remaining were greatly improved, were partially improved and 7 did not improve. As in atopic dermatitis, the major benefit was relief from pruritus. Nummula: eczema: Of the patients treated with the ointment or cream, were lost from observation. Among the patients followed, involution of lesions occurred in, were partially improved and were not improved. Stasis dermatitis: patients were treated with ointment or cream. Four were lost from observation, improved, partially improved and were not benefited. Erythrodermia desquamativa (Leiner's disease): Two infants with this condition were treated with the ointment. Prompt improvement was noted and all lesions subsided in two weeks. Pruritus ani: The results obtained in the treatment of this condition were not impressive. Fifteen of the patients were followed, 9 showing partial improvement, no improvement, and were lost from observation. When the medication was discontinued, the condition recurred. Miliaria rubra: Of this group of patients, were lost from observation, 7 of the remaining were relieved by the application of the cream, and was not benefited. Conditions not benefited (Table III) The medication proved to be of no value in herpes zoster, neurotic excoriations, lichen scierosus et atrophicus, tinea capitis, trichophytosis corporis, uncomplicated epidermophytosis, pityriasis rosea, acne vulgaris, vitiligo, verruca vulgaris, TABLE III Non-pyogenic skin disorders not benefitted by chlorquinaldol Diagnosis Cases Effect on Pruritus or Pain Herpes zoster Neurotic excoriations Lichen scierosus et atrophicus + Tinea capitis 9 Trichophytosis corporis Epidermophytosis, uncomplicated Pityriasis rosea Acne vulgaris Vitiligo Verruca vulgaris Varicella Dermatitis exfoliativa Erythema multiforme, papular IJrticaria Dermatitis medicamentosa Lichen planus +

TOPICAL USE OF CHLORQUINALDOL 7 varicella, dermatitis exfoliativa, papular erythema multiforme, uriticaria, dermatitis medicamentosa, lichen planus, and pustular bacterid. Reactions Reactions of specific hypersensitivity were found in five patieiits as demonstrated by positive patch tests. Nineteen patients developed evidence of primary irritation due to local application of the ointment or cream. The patch tests in this latter group gave negative results. SUMMARY AND CONCLUSIONS. Seven hundred fifty six patients with various dermatoses were treated with chlorquinaldol in an oily ointment base or greaseless base cream.. Chlorquinaldol proved to be of value in the topical treatment of pyodermas and other dermatoses complicated by secondary pyogenic infection.. These preparations are effective antipruritic agents.. Chlorquinaldol is also of value as an adjunct in the treatment of atopic dermatitis, seborrheic dermatitis, contact dermatitis, neurodermatitis, psoriasis, nummular eczema, stasis dermatitis, otitis externa, erythrodermia desquamativa, dermatitis exfoliative neonatorum, miliaria rubra and infectious eczematoid dermatitis. 5. The preparation proved to be of no value in the treatment of herpes zoster, neurotic excoriations, lichen sclerosus et atrophicus, tinea capitis, trichophytosis corporis, uncomplicated epidermophytosis, pityriasis rosea, acne vulgaris, vitiligo, verruca vulgaris, varicella, dermatitis exfoliativa, papular erythema multiforme, urticaria, dermatitis medicamentosa, lichen planus and pustular bacterid.. Six hundred fifty eight patients returned for follow-up examinations. Of these five developed a reaction of specific hypersensitivity and nineteen developed local irritative phenomena. REFERENCES. JADASSOHN, W., Fiz, H. E. AND PFANNER, E.: A new remedy (Sterosan) for the treatment of pyodermas. Schweiz. med. Wchnschr., 7:, 9.. METAXAS, M.: The effectiveners of -Oxyquinaldine derivatives on staphylococci in vitro. Diss., Zurich, 97.. FELKEL, J.: Experience in treating pyodermas and mycotic infections with sterosan. Prakt. Arzt, : 5, 95.. SIGG, K.: Treatment of mycosis of the foot and of mycotic eczema with sterosan, Schweiz. med. Wchnschr., 77:, 97. 5. SCHUBERT: Experience with sterosan. Ztschr. Haut- u. Geschlechtskr., : 7, 95.. BRUNI, G.: A new remedy for the treatment of various skin infections. Praxis, :, 95. 7. COHEN, E. L.: The treatment of impetigo and sycosis barbae with dichiorooxyquinaldine. M. Press, :, 95.. FAESSLER, J.: The effect of oxyquinoline derivatives on fungi and staphylococci. Diss., Zurich, 95. 9. PIERCE, H. E., JR.: A clinical evaluation of dichloroxyquinaldine in dermatology. J. Nat. M. A., 5: 7, 95.. LEIFER, W. AND STEINER, K.: Studies in sensitization to halogenated hydroxyquinolines and related compounds. J. Invest. Dermat., 7:, 95.